Regeneron Pharmaceuticals (REGN) said Thursday that its two investigational Factor XI antibodies showed "robust" antithrombotic effects with no clinically relevant bleeding observed in a phase 2 proof-of-concept study.
Monoclonal antibodies REGN7508 and REGN9933, which are being evaluated for potential to control thrombosis, were compared with standards of care and given 12 to 24 hours after total knee replacement in the study, the company said.
The company said it will test REGN7508 and REGN9933 in a phase 3 trial, expected to begin in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments